679 related articles for article (PubMed ID: 17559749)
21. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates in breast cancer.
Coleman RE
Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
[TBL] [Abstract][Full Text] [Related]
23. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
Cameron D
Breast; 2003 Aug; 12 Suppl 2():S22-9. PubMed ID: 14659140
[TBL] [Abstract][Full Text] [Related]
24. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
26. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Nelson A; Fenlon D; Morris J; Sampson C; Harrop E; Murray N; Wheatley D; Hood K; Griffiths G; Barrett-Lee P
Trials; 2013 Oct; 14():325. PubMed ID: 24107437
[TBL] [Abstract][Full Text] [Related]
27. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
28. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Body JJ
Breast; 2003 Aug; 12 Suppl 2():S37-44. PubMed ID: 14659142
[TBL] [Abstract][Full Text] [Related]
29. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates and metastatic breast carcinoma.
Lipton A
Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
[TBL] [Abstract][Full Text] [Related]
31. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
32. [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Schivazappa C; Berto P; Baldini E; Barni S; Dauria G; Cortesi E
Recenti Prog Med; 2008 Jan; 99(1):27-31. PubMed ID: 18389868
[TBL] [Abstract][Full Text] [Related]
33. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
Conte P; Guarneri V
Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
35. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
36. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Reed SD; Radeva JI; Glendenning GA; Coleman RE; Schulman KA
Am J Clin Oncol; 2005 Feb; 28(1):8-16. PubMed ID: 15685028
[TBL] [Abstract][Full Text] [Related]
39. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
40. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
